A repurposed drug used to treat arthritis did not significantly improve the outcomes of patients with severe COVID-19 pneumonia. Tocilizumab did not significantly improve clinical status or mortality rate at 28 days for participants who received it compared to a placebo, according to a new study.
from Latest Science News -- ScienceDaily https://ift.tt/2NQgYE1
via IFTTT
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment